Delayed Nasdaq - 11/17 10:00:02 pm
Syndax Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of cancer therapies.It focuses on the development and commercialization of its lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.The company...
2018-03-01 Earnings Release
|Trading Rating :|
|Investor Rating :|
Technical analysis trends
|Short Term||Mid-Term||Long Term|